Literature DB >> 3773832

Treatment of the barbiturate abstinence syndrome.

J T Sullivan, E M Sellers.   

Abstract

Patients with the barbiturate abstinence syndrome require pharmacotherapy (and hospitalization) when there is a history of the ingestion of greater than 0.4 g of secobarbital or its equivalent for 90 or more days, or of 0.6 g for 30 or more days, or a previous history of barbiturate withdrawal seizures or delirium. The pharmacological management of withdrawal, which is rational, safe, efficacious and relatively simple, is described and recommended. This treatment relies on a phenobarbital loading-dose technique which is titrated to clinical end-points. The prolonged elimination of phenobarbital prevents the reappearance of withdrawal symptoms and, since repeated doses are not required, results in less manipulative drug-seeking behaviour.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3773832

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  3 in total

1.  Hypertension and pulmonary oedema associated with ketamine administration in a patient with a history of substance abuse.

Authors:  J L Murphy
Journal:  Can J Anaesth       Date:  1993-02       Impact factor: 5.063

2.  Alcohol, barbiturate and benzodiazepine withdrawal syndromes: clinical management.

Authors:  E M Sellers
Journal:  CMAJ       Date:  1988-07-15       Impact factor: 8.262

Review 3.  Should butalbital-containing analgesics be banned? Yes.

Authors:  William B Young; Hua Chiang Siow
Journal:  Curr Pain Headache Rep       Date:  2002-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.